Chicago Partners Investment Group’s Janux Therapeutics JANX Stock Holding History

Chicago Partners Investment Group’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,621	Closed	-$235K	–	965
2024 Q4	$235K	Sell	4,621 -630	-12%	-$33.3K	0.01%	753
2024 Q3	$272K	Buy	+5,251	New	+$228K	0.01%	651
2024 Q2	–	Sell	-8,464	Closed	-$421K	–	756
2024 Q1	$421K	Buy	+8,464	New	+$184K	0.02%	495
2022 Q4	–	Sell	-10,621	Closed	-$181K	–	651
2022 Q3	$181K	Buy	+10,621	New	+$142K	0.01%	543
2022 Q1	–	Sell	-11,380	Closed	-$188K	–	589
2021 Q4	$188K	Buy	11,380 +1,922	+20%	+$40.3K	0.01%	533
2021 Q3	$235K	Buy	+9,458	New	+$272K	0.02%	503

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Chicago Partners Investment Group's JANX Position: Q1 2025 in Review

Chicago Partners Investment Group sold out of Janux Therapeutics (JANX) in Q1 2025, closing a stake of 4,621 shares — an estimated $235K sold.

Chicago Partners Investment Group first reported a position in JANX in Q3 2021 and held it in 6 quarters. The position peaked at $421K in Q1 2024. 181 funds tracked by Wall St. Rank hold JANX as of Q1 2025.

Chicago Partners Investment Group reported no remaining Janux Therapeutics position as of Q1 2025 after selling out during the quarter.
Chicago Partners Investment Group sold 4,621 Janux Therapeutics shares in Q1 2025, an estimated $235K.
Chicago Partners Investment Group first reported a position in Janux Therapeutics in Q3 2021 and held it in 6 quarters.
Chicago Partners Investment Group's Janux Therapeutics position peaked at $421K in Q1 2024.
181 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2025.

Based on Chicago Partners Investment Group's 13F filing for Q1 2025, filed 9 May 2025.